biotechs

Small, mid-size biotechs could see M&A action in H2

designer491 As many large pharmas continue to deal with upcoming patent cliffs that will impact sales of key drugs, it could spur additional dealmaking for small and mid-size biotechs to make up for the loss of revenue. These biotechs will “will receive significant attention in 2024″ as a way toContinue Reading

Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2

In: Finance

Alnylam Pharmaceuticals (NASDAQ:ALNY) was the best performing large cap ($30B+) pharma or biotech in Q2, returning ~58.5% in the period. The biotech’s strong performance was helped significantly in late June when it reported strong pivotal trial results for vutrisiran, a treatment for ATTR amyloidosis with cardiomyopathy, sending shares skyrocketing. FollowingContinue Reading

Small, mid-size biotechs could see M&A action in H2

Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2

How Rocket Companies modernized their data science solution on AWS | Amazon Web Services

AWS and DXC collaborate to deliver customizable, near real-time voice-to-voice translation capabilities for Amazon Connect | Amazon Web Services